AI GxP validation for regulated life sciences
Test Automation

Automated Execution in an Inspection: The Questions You Will Be Asked

Inspectors are not opposed to automation. They are opposed to evidence they cannot follow. The questions that come up, and what a good answer looks like with the record open in front of you.

Cybroscape Technologies4 min read

Key takeaway

Inspectors are not opposed to automation. They are opposed to evidence they cannot follow. The questions that come up, and what a good answer looks like with the record open in front of you.

Inspectors are not hostile to automation. In our experience they are mildly relieved by it — automated evidence tends to be more consistent than the handwritten kind, and it does not have gaps where somebody got busy.

What they object to is evidence they cannot follow. The questions below are the ones that come up, and each has a good answer if the system was built with them in mind.

“Show me the protocol that produced this result.”

The opener, and it is a trap only if your results reference a protocol by name rather than by version. Revise a protocol after a run and the name now points at something that was never executed.

A good answer pulls up the exact approved version, its signature, and the run that used it, in that order. If getting there involves a spreadsheet mapping run IDs to document revisions, the follow-up questions will be harder.

“Who approved this test, and what did they see?”

The second part is the real question. An approval signature against a protocol that reads run: verify-all.sh is a signature against a filename — and that is the moment a closed vocabulary stops being an architectural preference and starts being the answer to an inspector.

What you want to be able to say: the approver saw every step in the terms you are reading now, because there is no layer underneath them.

“How do you know the tool reports failures correctly?”

This is the question teams are least ready for, because all their evidence is of things passing. The answer is a negative test set — deliberately failing tests that the tool must report as failures — run as part of tool qualification and re-run on version change.

It takes a day to build and it converts a difficult question into a short one. More on the scope in qualifying the tool itself.

“What happened to this failed run?”

They will find one. A system with no failed runs looks less credible, not more, and an inspector who sees only passes will start wondering what happened to the rest.

The good answer is a closed loop: the failure, the investigation, the conclusion, and the deviation if there was one. The bad answer is a failed run followed by a passing re-run and nothing in between — see why a passing re-run is not an explanation.

“Is AI involved in this?”

Increasingly common, and it is a fair question rather than a hostile one. The answer is much easier if the three roles were kept apart from the start: AI may have drafted the protocol, a named person approved it, and a deterministic engine executed it with no model involved at run time.

That sentence answers the question completely, and it is checkable. See the three roles and AI validation services.

“Can it reach production?”

The last one, and the shortest. "No — it is configured to reach these hosts, here is the configuration" ends the line of questioning. "It could, but our procedure says not to" opens a longer one about how that procedure is enforced. Configured reach is a much easier thing to defend than a rule.

Where to go next

Explore Cybroscape GxP Copilot for AI-native validation, Cybroscape TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.

High riskFailure could affect patient safety or product quality
Scripted testingWritten steps, expected results, an independent reviewer
Step-by-step results, screenshots and signatures
Medium riskFailure is noticed and contained
Unscripted testingExploratory or ad-hoc testing against the intended use
A record of what was tested, by whom, and the result
Low riskStandard function, supplier-tested
Supplier evidenceThe vendor’s own testing, assessed and accepted
The assessment and the reason it is enough
Computer Software Assurance in one picture: test effort follows the risk of each requirement. Based on FDA’s Computer Software Assurance guidance.
See it on your own systemBring a URS or a system. We run GxP Copilot against it live on the call.
inspection automated testingfda inspection test automationdefending automation inspectorvalidation inspection readinessaudit automated execution

Keep reading

All articles
RIMIDMP and eCTD 4.0: both expose the same master data problemIDMP and eCTD 4.0 both depend on consistent product master data. The readiness work is one agreed source of truth, named owners, and change control that keeps regulatory data current. · 3 min readEquipment QualificationInstrument qualification is not equipment qualification: USP <1058> vs Annex 15A balance, an autoclave and a chromatography data system are three different regulatory problems. Which framework applies to what, and why the join is where the defects are. · 7 min readLIMSLIMS validation in 2026: a modern playbook for LabWare, LabVantage, STARLIMS and BenchlingInstrument interfaces, sample lifecycle, ALCOA+ data integrity, with the right test strategy per LIMS. · 8 min readMed DeviceMDR CERs with AI: traceable clinical claims, hash-chained auditThe MDR clinical evidence burden meets a source-traceable AI writing platform. · 5 min readMESMES validation for pharma: PAS-X, Opcenter, Rockwell, KörberRecipes, EBR, weigh & dispense: a CSA-native MES validation approach. · 7 min readThought LeadershipThe mid-market validation gap: why a 200-person biotech carries big-pharma paperworkGrowing biotechs often copy large-pharma validation templates and get the cost without the context. Right-sized validation puts effort on high-risk systems and functions, relies on assessed vendor evidence, and invests in staying validated. · 3 min readDigital TransformationPaperless Validation Software: The 2026 Buyer's GuideWhat paperless (digital) validation software has to do, the regulatory basis under Part 11, Annex 11 and CSA, the products buyers shortlist in 2026, and how to move off paper in about 90 days. · 11 min readManufacturing AIPharmaceutical Batch Failure AI: How Predictive Analytics Prevents OOS Events and Manufacturing DeviationsHow AI is being applied to pharmaceutical batch failure prevention: root cause analysis, OOS investigation, process analytical technology, and the validated data infrastructure that makes predictive models GxP-defensible. · 8 min read

Bring a system. We'll show you the package.

Book a demo, or ask a validation lead a quick question on WhatsApp.

  • We reply within one business day
  • We run your URS live on the call
  • You get a clear plan for your system
Chat on WhatsApp

Book a demo

Four fields. The right specialist replies within one business day.

Your details stay private. We never share them.